サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：非ホジキンリンパ腫治療薬の世界市場規模調査＆予測：疾患タイプ別、流通チャネル別、地域別分析、2022-2029年
市場調査レポート
商品コード
1251575

非ホジキンリンパ腫治療薬の世界市場規模調査＆予測：疾患タイプ別、流通チャネル別、地域別分析、2022-2029年

Global Non - Hodgkin Lymphoma Therapeutics Market Size study & Forecast, by Type of Therapy by Disease Type, by Distribution Channel and Regional Analysis, 2022-2029
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
非ホジキンリンパ腫治療薬の世界市場規模調査＆予測：疾患タイプ別、流通チャネル別、地域別分析、2022-2029年
出版日: 2023年03月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の非ホジキンリンパ腫治療薬市場は、2021年に約83億3,000万米ドルと評価され、予測期間2022-2029年には約8.50%の健全な成長率で成長すると予測されています。

非ホジキンリンパ腫（NHL）は、人体内で異常なリンパ球が生成される疾患です。これらのリンパ球は死滅せず、治療しない限り体内で増殖・分裂を続けます。NHLは一般的にリンパ節に発生しますが、治療が間に合わなければ、リンパ系全体に転移する可能性があります。非ホジキンリンパ腫治療薬市場は、タイプ、治療タイプ、投与経路、流通チャネル、エンドユーザーに基づいて細分化されます。産業の市場成長は、これらのセグメントの成長から検査を取得し、ユーザーがあなたに市場の洞察を概観し、コア市場のアプリケーションを分類するための意思決定を行うのに役立ちます。

非ホジキンリンパ腫のイベントが増加し、市場成長につながる、また、非ホジキンリンパ腫のいくつかのタイプも含む、ほぼすべてのタイプのがんの高い有病率の現在の動向である難治性または悪化している非ホジキンリンパ腫の患者のためのより良い臨床および救済結果の必要性が重要な促進要因です。多くの種類の非ホジキンリンパ腫に対する効率的な治療薬の開発における研究開発の継続と増加が、主な促進要因の1つとなっています。また、市場関係者による投資の増加も、長期的な成長の要因となっています。また、経口薬の需要の高まりも、ほとんどの製品がカプセルやタブレットの形で提供されている市場の成長に寄与しています。

新興国における承認済み治療薬のコスト増は、先進的な治療薬の採用を抑制する要因となっています。非ホジキンリンパ腫治療市場の成長は、免疫療法のような特定の種類の治療に課される高いコストに影響されています。非ホジキンリンパ腫の治療法に関する知識を持たない訓練された専門家の不足は、予測期間中、世界の非ホジキンリンパ腫市場の成長を抑制する可能性があります。

また、国民の健康意識の高まりも、市場の成長を大きく後押ししています。米国がん協会によると、非ホジキンリンパ腫は約80,470人いると推定されています。最も高い発生率は、女性では80-84歳、男性では85-89歳の間の年齢層であると思われます。患者を効果的に治療するために、より良い臨床の必要性がますます高まっており、これが市場成長の原動力となっています。

非ホジキンリンパ腫治療薬の世界市場調査において考慮した主要地域は、アジア太平洋地域、北米、欧州、中南米、その他世界の地域です。北米は、非ホジキンリンパ腫のような様々な血液がんを含むあらゆる形態のがんに対する高い有病率と認知度により、市場を独占しています。このため、非ホジキンリンパ腫の治療には、免疫療法などの高価な治療法が採用されるようになりました。アジア太平洋地域は、予測期間中に最も急速に成長する市場です。アジア太平洋地域の日本は、人口が多く、アジア太平洋市場の成長に貢献するキミアなどの高価な治療薬を承認しています。

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界・セグメント別市場推定・予測、2019年～2029年
    • 非ホジキンリンパ腫治療薬市場、地域別、2019-2029年
    • 非ホジキンリンパ腫治療薬市場、治療法別、2019-2029年
    • 非ホジキンリンパ腫治療薬市場、疾患別、2019-2029年
    • 非ホジキンリンパ腫治療薬市場、流通別、2019-2029年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 世界の非ホジキンリンパ腫治療薬市場の定義とスコープ

  • 調査目的
  • 市場の定義と範囲
    • 調査対象範囲
    • 産業の進化
  • 本調査の対象となった年
  • 通貨換算レート

第3章 非ホジキンリンパ腫治療薬の世界市場力学

  • 非ホジキンリンパ腫治療薬の市場インパクト分析（2019-2029年）
    • 市場促進要因
      • 市場関係者別投資の増加
      • 経口薬の需要増
    • 市場の課題
      • 非ホジキンリンパ腫の高額な治療費について
    • マーケットオポチュニティ
      • 非ホジキンリンパ腫の増加
      • 高まるヘルスケアへの意識

第4章 非ホジキンリンパ腫治療薬の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
  • PEST分析
    • 政治的
    • 経済的
    • ソーシャル
    • テクニカル
  • 投資採用モデル
  • アナリストの提言と結論
  • 最高の投資機会
  • 主要成功戦略

第5章 リスクアセスメントCOVID-19の衝撃

  • COVID-19が業界に与える全体的な影響についての評価
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 非ホジキンリンパ腫治療薬の世界市場：治療法別

  • マーケットスナップショット
  • 非ホジキンリンパ腫治療薬の世界市場：治療法別、業績別-潜在能力分析
  • 非ホジキンリンパ腫治療薬の世界市場治療法別推定・予測2019-2029
  • 非ホジキンリンパ腫治療薬市場、サブセグメント別分析
    • 化学療法
    • 標的療法
    • 免疫療法
    • その他

第7章 非ホジキンリンパ腫治療薬の世界市場：疾患タイプ別

  • マーケットスナップショット
  • 非ホジキンリンパ腫治療薬の世界市場：疾患タイプ別、パフォーマンス-ポテンシャル分析
  • 非ホジキンリンパ腫治療薬の世界市場疾患タイプ別推定・予測2019-2029
  • 非ホジキンリンパ腫治療薬市場、サブセグメント別分析
    • B細胞性リンパ腫
    • T細胞性リンパ腫

第8章 非ホジキンリンパ腫治療薬の世界市場：流通チャネル別

  • マーケットスナップショット
  • 非ホジキンリンパ腫治療薬の世界市場：流通チャネル別、業績-ポテンシャル分析
  • 非ホジキンリンパ腫治療薬の世界市場流通チャネル別推定・予測2019-2029
  • 非ホジキンリンパ腫治療薬市場、サブセグメント別分析
    • 病院内薬局
    • 小売薬局
    • その他

第9章 非ホジキンリンパ腫治療薬の世界市場：地域別分析

  • 非ホジキンリンパ腫治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
      • 療法別の推定・予測、2019年～2029年
      • 疾患タイプ別の推定・予測、2019年～2029年
      • 流通チャネル別の推定・予測、2019年～2029年
    • カナダ
  • 欧州非ホジキンリンパ腫治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋非ホジキンリンパ腫治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ非ホジキンリンパ腫治療薬市場スナップショット
    • ブラジル
    • メキシコ
  • 世界のその他の地域

第10章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Takeda Pharmaceutical Company Limited
      • 主要な情報
      • 概要
      • 財務（データの入手が可能な場合のみ）
      • 製品概要
      • 最近の動向
    • AstraZeneca plc
    • Bayer AG
    • Novartis AG
    • Kyowa Kirin Co. Ltd.
    • Bristol Myers Squibb Company
    • Janssen Pharmaceuticals Inc.
    • Merck & Co. Inc.
    • Sanofi India
    • AbbVie. Inc

第11章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Non-Hodgkin lymphoma treatment Market, report scope
  • TABLE 2. Global Non-Hodgkin lymphoma treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Non-Hodgkin lymphoma treatment Market estimates & forecasts by Therapy 2019-2029 (USD Billion)
  • TABLE 4. Global Non-Hodgkin lymphoma treatment Market estimates & forecasts by Disease type 2019-2029 (USD Billion)
  • TABLE 5. Global Non-Hodgkin lymphoma treatment Market estimates & forecasts by Distribution channel 2019-2029 (USD Billion)
  • TABLE 6. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Non-Hodgkin lymphoma treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Non-Hodgkin lymphoma treatment Market by Region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. U.S. Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 20. Canada Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. Canada Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 23. UK Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. UK Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 26. Germany Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. Germany Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 29. France Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. France Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 32. Italy Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Italy Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 35. Spain Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. Spain Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 38. RoE Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. RoE Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 41. China Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. China Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 44. India Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. India Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 47. Japan Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. Japan Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 50. South Korea Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. South Korea Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 53. Australia Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. Australia Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 59. Brazil Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Brazil Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 62. Mexico Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. Mexico Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 65. RoLA Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. RoLA Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Non-Hodgkin lymphoma treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 68. Row Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. Row Non-Hodgkin lymphoma treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Non-Hodgkin lymphoma treatment Market
  • TABLE 71. List of primary sources, used in the study of global Non-Hodgkin lymphoma treatment Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Non-Hodgkin lymphoma treatment Market, research methodology
  • FIG 2. Global Non-Hodgkin lymphoma treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Non-Hodgkin lymphoma treatment Market, key trends 2021
  • FIG 5. Global Non-Hodgkin lymphoma treatment Market, growth prospects 2022-2029
  • FIG 6. Global Non-Hodgkin lymphoma treatment Market, porters 5 force model
  • FIG 7. Global Non-Hodgkin lymphoma treatment Market, pest analysis
  • FIG 8. Global Non-Hodgkin lymphoma treatment Market, value chain analysis
  • FIG 9. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Non-Hodgkin lymphoma treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Non-Hodgkin lymphoma treatment Market, Regional snapshot 2019 & 2029
  • FIG 15. North America Non-Hodgkin lymphoma treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Non-Hodgkin lymphoma treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Non-Hodgkin lymphoma treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Non-Hodgkin lymphoma treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Non-Hodgkin lymphoma treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Non - Hodgkin Lymphoma Therapeutics Market is valued at approximately USD 8.33 billion in 2021 and is anticipated to grow with a healthy growth rate of around 8.50% over the forecast period 2022-2029. Non- Hodgkin lymphoma (NHL) is a condition where abnormal lymphocytes are produced in the human body. These lymphocytes do not die and keep growing and dividing within the body unless treated. NHL is generally located at lymph nodes, however, if not treated in time, then it might spread to the entire lymphatic system. The Non- Hodgkin lymphoma therapeutics market is subdivided on basis of type, treatment type, route of administration, distribution channel and end user. The market growth of industries will get inspected from the growth of these segments and help the users to overview you the market insights and helps to make decisions for classifying core market application.

Increasing events of Non-Hodgkin Lymphomas lead to Market Growth and are the current trends of higher prevalence of almost all types of cancer which also includes several types of NHL The need for better clinical and remedial results for the patients for non-Hodgkin lymphoma where the disease has become refractory or deteriorated is a critical driving factor. Ongoing and increased R&D activity in the development of efficient therapeutics for a number of types of NHL are one of the key driving factors. Along with an increasing investment by market players also a factor for long term growth. The rising demand for oral drugs has also contributed to the market growth where most products are available in capsule and tablet form.

Increased cost of approved Therapeutics in Emerging countries leads to curb the Adoption of advanced Therapeutics. The non-Hodgkin lymphoma treatment market growth is affected by the high cost imputed to certain types of therapies like immunotherapies. Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global non-Hodgkin lymphoma market over a forecast period.

As Health Awareness increasing among the population also indicates a major boost to the market growth. According to the American Cancer Society, non-Hodgkin lymphoma is estimated to be around 80, 470. The Highest rates are likely to be in the age group between 80-84 years for females and 85-89 years for males. The need for better clinical are required more and more to treat the patients effectively which drives the market growth.

The key regions considered for the Global Non - Hodgkin Lymphoma Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominates the market due to high prevalence and awareness of all forms of cancer including various blood cancers such as non-Hodgkin's lymphoma. These led to adoption of expensive form of therapies for treatment of NHL such as immunotherapies. Asia Pacific is going to be the fastest growing market in the forecasted period, Japan in Asia Pacific has approved the expensive therapeutics such as KYMRIAH which holds strong population base and well contribute in the Asia Pacific market growth.

Major market players included in this report are:

  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Bayer AG
  • Novartis AG
  • Kyowa Kirin Co. Ltd.
  • Bristol Myers Squibb Company
  • Janssen Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Sanofi India
  • AbbVie Inc.

Recent Developments in the Market:

  • April 2021 - Kyowa Kirin Co., Ltd. and MEI Pharma Inc. announced the completion of patient enrollment in the global Phase 2 TIDAL study in the primary efficacy follicular lymphoma population.
  • April 2021 - Kyowa Kirin Co., Ltd. and MEI Pharma Inc. announced the completion of patient enrollment in the gl primary efficacy population for follicular lymphoma. * February 2021 - Bristol-Myers Squibb Company Receives FDA Approval of CAR T-Cell Therapy Breyanzi for the Treatment of Large B-Cell Lymphoma in Patients Who Relapsed After Two Other Systematic Treatments or Responded to Previous Therapy announced that it had received Treatment has not been addressed.
  • December 2020 - AstraZeneca announced that Calquence, an anti-cancer drug used to treat patients with mantle cell lymphoma, has shown positive responses in a Phase 2 clinical trial.

Global Non - Hodgkin Lymphoma Therapeutics Market Report Scope:

  • Historical Data 2019-2020-2021
  • Base Year for Estimation 2021
  • Forecast period 2022-2029
  • Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered By Therapy, Disease Type, Distribution channel, Region
  • Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapy:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Others

By Disease Type:

  • B-cell Lymphoma
  • T-cell Lymphoma

By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Non-Hodgkin lymphoma treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Non-Hodgkin lymphoma treatment Market, by Therapy, 2019-2029 (USD Billion)
    • 1.2.3. Non-Hodgkin lymphoma treatment Market, by Disease, 2019-2029 (USD Billion)
    • 1.2.4. Non-Hodgkin lymphoma treatment Market, by Distribution, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Non-Hodgkin lymphoma treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Non-Hodgkin lymphoma treatment Market Dynamics

  • 3.1. Non-Hodgkin lymphoma treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing investments by Market players
      • 3.1.1.2. Rising Demand for oral drugs
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Non-Hodgkin lymphoma treatment
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in Non-Hodgkin Lymphoma
      • 3.1.3.2. Rising Healthcare Awareness

Chapter 4. Global Non-Hodgkin lymphoma treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Non-Hodgkin lymphoma treatment Market, by Therapy

  • 6.1. Market Snapshot
  • 6.2. Global Non-Hodgkin lymphoma treatment Market by Therapy, Performance - Potential Analysis
  • 6.3. Global Non-Hodgkin lymphoma treatment Market Estimates & Forecasts by Therapy 2019-2029 (USD Billion)
  • 6.4. Non-Hodgkin lymphoma treatment Market, Sub Segment Analysis
    • 6.4.1. Chemotherapy
    • 6.4.2. Targeted Therapy
    • 6.4.3. Immunotherapy
    • 6.4.4. Others

Chapter 7. Global Non-Hodgkin lymphoma treatment Market, by Disease type

  • 7.1. Market Snapshot
  • 7.2. Global Non-Hodgkin lymphoma treatment Market by Disease type, Performance - Potential Analysis
  • 7.3. Global Non-Hodgkin lymphoma treatment Market Estimates & Forecasts by Disease type 2019-2029 (USD Billion)
  • 7.4. Non-Hodgkin lymphoma treatment Market, Sub Segment Analysis
    • 7.4.1. B-Cell Lymphoma
    • 7.4.2. T-cell Lymphoma

Chapter 8. Global Non-Hodgkin lymphoma treatment Market, by Distribution channel

  • 8.1. Market Snapshot
  • 8.2. Global Non-Hodgkin lymphoma treatment Market by Distribution channel, Performance - Potential Analysis
  • 8.3. Global Non-Hodgkin lymphoma treatment Market Estimates & Forecasts by Distribution channel 2019-2029 (USD Billion)
  • 8.4. Non-Hodgkin lymphoma treatment Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail pharmacies
    • 8.4.3. Others

Chapter 9. Global Non-Hodgkin lymphoma treatment Market, Regional Analysis

  • 9.1. Non-Hodgkin lymphoma treatment Market, Regional Market Snapshot
  • 9.2. North America Non-Hodgkin lymphoma treatment Market
    • 9.2.1. U.S. Non-Hodgkin lymphoma treatment Market
      • 9.2.1.1. Therapy breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Disease type breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Distribution channel breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Non-Hodgkin lymphoma treatment Market
  • 9.3. Europe Non-Hodgkin lymphoma treatment Market Snapshot
    • 9.3.1. U.K. Non-Hodgkin lymphoma treatment Market
    • 9.3.2. Germany Non-Hodgkin lymphoma treatment Market
    • 9.3.3. France Non-Hodgkin lymphoma treatment Market
    • 9.3.4. Spain Non-Hodgkin lymphoma treatment Market
    • 9.3.5. Italy Non-Hodgkin lymphoma treatment Market
    • 9.3.6. Rest of Europe Non-Hodgkin lymphoma treatment Market
  • 9.4. Asia-Pacific Non-Hodgkin lymphoma treatment Market Snapshot
    • 9.4.1. China Non-Hodgkin lymphoma treatment Market
    • 9.4.2. India Non-Hodgkin lymphoma treatment Market
    • 9.4.3. Japan Non-Hodgkin lymphoma treatment Market
    • 9.4.4. Australia Non-Hodgkin lymphoma treatment Market
    • 9.4.5. South Korea Non-Hodgkin lymphoma treatment Market
    • 9.4.6. Rest of Asia Pacific Non-Hodgkin lymphoma treatment Market
  • 9.5. Latin America Non-Hodgkin lymphoma treatment Market Snapshot
    • 9.5.1. Brazil Non-Hodgkin lymphoma treatment Market
    • 9.5.2. Mexico Non-Hodgkin lymphoma treatment Market
  • 9.6. Rest of The World Non-Hodgkin lymphoma treatment Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Takeda Pharmaceutical Company Limited
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. AstraZeneca plc
    • 10.2.3. Bayer AG
    • 10.2.4. Novartis AG
    • 10.2.5. Kyowa Kirin Co. Ltd.
    • 10.2.6. Bristol Myers Squibb Company
    • 10.2.7. Janssen Pharmaceuticals Inc.
    • 10.2.8. Merck & Co. Inc.
    • 10.2.9. Sanofi India
    • 10.2.10. AbbVie. Inc

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption